Swinnen Ans, Verstraete Jan, Huyskens Dominique Pierre
Division of Radiation Physics, Department of Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
Radiother Oncol. 2004 Oct;73(1):89-96. doi: 10.1016/j.radonc.2004.07.021.
The aim of this work is to set-up mailed entrance in vivo dosimetry by means of thermoluminescence dosimeters (TLDs) in the form of LiF powder in order to assess the overall accuracy of patient treatment delivery by comparing the doses delivered to patients with the doses calculated by the treatment planning system (TPS) in different institutions.
Two millimeter thick copper (for 6 MV photon beams) and 1.3 mm thick aluminium (for (60)Co gamma beams) build-up caps are developed. The characteristics of these build-up caps are tested by phantom measurements: the response of the TLD inside the build-up cap is compared to the ionisation chamber (IC) signal in the same irradiation conditions. A pilot study using the copper build-up cap is performed on 8 patients, treated with a 6 MV photon beam at the radiotherapy department of the University Hospital of Leuven. Additionally, a first run of mailed entrance in vivo dosimetry is performed by 18 radiotherapy centres in Europe.
For 80 different phantom set-ups using copper and aluminium build-up caps, the mean TLD dose compared to the IC dose is 0.993+/-0.015 (1SD). Regarding the patient measurements in the radiotherapy department of the University Hospital of Leuven, the mean ratio of the measured entrance dose (TLD) to the entrance dose calculated by the TPS, is equal to 0.986+/-0.017 (1SD) (N=8), after correction of an error detected in one of the patient treatments. For the 18 radiotherapy centres participating in the mailed in vivo TLD study, the mean measured versus stated entrance dose for patients treated in a (60)Co and 6 MV photon beam is 1.004+/-0.021 (1SD) (N=143).
From the results, it can be deduced that the build-up caps and the proposed calibration methodology allow the use of TLD in the form of powder to be applied in large scale in vivo dose audits.
本研究旨在通过使用LiF粉末形式的热释光剂量计(TLD)建立邮寄式体内剂量测定法,以便通过比较不同机构中患者接受的剂量与治疗计划系统(TPS)计算的剂量,评估患者治疗剂量传递的整体准确性。
开发了厚度为2毫米的铜制(用于6 MV光子束)和厚度为1.3毫米的铝制(用于钴 - 60伽马射线束)建成帽。通过模体测量测试这些建成帽的特性:在相同照射条件下,将建成帽内TLD的响应与电离室(IC)信号进行比较。在鲁汶大学医院放疗科,对8例接受6 MV光子束治疗的患者进行了使用铜制建成帽的初步研究。此外,欧洲18个放疗中心进行了首次邮寄式体内剂量测定。
对于使用铜制和铝制建成帽的80种不同模体设置,与IC剂量相比,TLD剂量的平均值为0.993±0.015(1标准差)。关于鲁汶大学医院放疗科的患者测量,在纠正了其中一次患者治疗中检测到的误差后,测量的入射剂量(TLD)与TPS计算的入射剂量的平均比值等于0.986±0.017(1标准差)(N = 8)。对于参与邮寄式体内TLD研究的18个放疗中心,在钴 - 60和6 MV光子束治疗的患者中,测量的与声明的入射剂量的平均值为1.004±0.021(1标准差)(N = 143)。
从结果可以推断,建成帽和所提出的校准方法允许将粉末形式的TLD大规模应用于体内剂量审核。